Genetic Signatures (GSS) Q1 2025 TU earnings summary

Executive summary

• Achieved quarterly sales of $4.7 million, up 294% year-over-year, driven by resumed Australian sales of EasyScreen Respiratory Pathogen Detection Kit during winter season.

• Strong US customer pipeline for EasyScreen Gastrointestinal Parasite Detection Kit, with over 60 sites engaged and several at final contract negotiation stage.

• Enhanced market awareness through participation in key US industry conferences and engagement with Key Opinion Leaders.

• Leadership changes include Allison Rossiter commencing as CEO and board renewal with new appointments.

Financial highlights

• Quarterly sales reached $4.7 million, compared to $1.2 million in the prior corresponding period (excluding COVID test sales).

• Receipts from customers were $7.0 million, up 99% year-over-year.

• Operating cash outflow was $2.7 million, mainly due to increased inventory and production costs.

• Net investing cash outflows totaled $0.2 million, including IP development and equipment investments.

• Cash balance at quarter end was $41.3 million, bolstered by a $30 million capital raise.

Outlook and guidance

• Focus remains on expanding US market presence following FDA clearance of the EasyScreen Gastrointestinal Parasite Detection Kit.

• Strong cash position supports continued innovation in assay development, workflow enhancements, and software.